Schizophrenia treatment urgently requires drugs targeting negative symptoms; report

The schizophrenia market across the seven major markets of the USA, France, Germany, Italy, Spain, the UK, and Japan, is set to rise from $6.4 billion in 2015 to $7.3 billion by 2025, registering a compound annual growth rate of 1.4%.

According to research and consulting firm GlobalData’s latest report, the major drivers of this modest growth include the uptake of novel pipeline products that have been designed to satisfy unmet needs in the disease and development of long-acting injectable (LAI) formulations of atypical antipsychotics in order to improve patient compliance, a notable unmet need.

However, Christos Michaelides, GlobalData’s analyst covering neurology and ophthalmology, notes: “While schizophrenia market growth will primarily be driven by the arrival of late-stage pipeline products, such as Minerva Neurosciences’ [Nasdaq: NERV] MIN-101 and Intra-Cellular Therapies’ [Nasdaq: ITCI] ITI-007, both of which are directed towards the treatment of negative symptoms associated with schizophrenia, these symptoms will remain a significant unmet need in the space.”